On July 31, 2018, Hansoh’s Punuoan ( Ambrisentan Tablets) received NDA approval from National Medical Products Administration to launch as a Category 4 first-to-market generic under the new classification system for registration of chemical drugs, equivalent to passing the consistency evaluation.

Ambrisentan is a highly selective endothelin receptor antagonist for the treatment of patients with pulmonary hypertension with WHO (World Health Organization) Class II or III symptoms.